CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,265 Shares

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 5,265 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $16.83, for a total value of $88,609.95. Following the completion of the sale, the vice president directly owned 19,384 shares of the company’s stock, valued at $326,232.72. The trade was a 21.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CeriBell Trading Up 3.0%

CBLL stock traded up $0.57 during trading on Friday, reaching $19.72. The company had a trading volume of 537,742 shares, compared to its average volume of 304,204. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The business has a 50 day moving average of $13.27 and a 200 day moving average of $14.40. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The company has a market cap of $731.61 million, a P/E ratio of -13.06 and a beta of 1.35.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. As a group, sell-side analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CBLL shares. Raymond James Financial initiated coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price for the company. JPMorgan Chase & Co. cut their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. TD Cowen decreased their price target on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell has a consensus rating of “Moderate Buy” and an average target price of $25.17.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell during the 3rd quarter valued at about $33,000. Tower Research Capital LLC TRC increased its stake in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its position in shares of CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after buying an additional 3,502 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in CeriBell during the 3rd quarter worth approximately $135,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.